Genetically modified Poliovirus (PVS-RIPO)
| Property | Information |
|---|---|
| Drug Name | Genetically modified Poliovirus (PVS-RIPO) |
| FDA Approval | Not specified |
| Used for | Not specified |
| Clinical Trial Phase | Not specified |
| Clinical Trial Explanation | Not specified |
| Common Side Effects | Not specified |
| OS without | Not specified |
| OS with | Not specified |
| PFS without | Not specified |
| PFS with | Not specified |
| Usefulness Rating | Not rated |
| Usefulness Explanation | Not specified |
| Toxicity Level | Not specified |
| Toxicity Explanation | Not specified |
From Ben Williams Book: In 2015, this phase I trial for recurrent glioblastoma at Duke University received a boost in public interest when an episode of the television show 60 minutes was devoted to it. Most exceptionally, the first two patients treated in this study were complete responders. As of March 2015 (when the 60 minutes special aired) these two complete responders were still alive and progression-free at 33 and 34 months from treatment. 11 of 22 patients in the trial were still alive, though six of these patients were less than 6 months from treatment. Importantly, dose escalation of PVS-RIPO failed to improve efficacy, and the more recent patients in the trial are being treated with a smaller dose than the trial originally started with. Read an interview with Darrel Bigner discussing this trial here.Property "Has original text" (as page type) with input value "In 2015, this phase I trial for recurrent glioblastoma at Duke University received a boost</br>in public interest when an episode of the television show 60 minutes was devoted to it.</br>Most exceptionally, the first two patients treated in this study were complete responders.</br>As of March 2015 (when the 60 minutes special aired) these two complete responders</br>were still alive and progression-free at 33 and 34 months from treatment. 11 of 22</br>patients in the trial were still alive, though six of these patients were less than 6 months</br>from treatment. Importantly, dose escalation of PVS-RIPO failed to improve efficacy, and</br>the more recent patients in the trial are being treated with a smaller dose than the trial</br>originally started with. Read an interview with Darrel Bigner discussing this trial here." contains invalid characters or is incomplete and therefore can cause unexpected results during a query or annotation process.
